Coherus Oncology/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus Oncology
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Ticker
$CHRS
Sector
Primary listing
Employees
147
Headquarters
Website
Coherus Oncology Metrics
BasicAdvanced
$252M
1.17
$1.43
1.09
-
Price and volume
Market cap
$252M
Beta
1.09
52-week high
$2.62
52-week low
$0.71
Average daily volume
1.8M
Financial strength
Current ratio
1.472
Quick ratio
1.357
Long term debt to equity
86.105
Total debt to equity
89.101
Interest coverage (TTM)
-19.60%
Profitability
EBITDA (TTM)
-172.51
Gross margin (TTM)
67.24%
Net profit margin (TTM)
398.43%
Operating margin (TTM)
-418.37%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-31.20%
Return on equity (TTM)
516.02%
Valuation
Price to earnings (TTM)
1.171
Price to revenue (TTM)
4.667
Price to book
3.34
Price to tangible book (TTM)
13.78
Price to free cash flow (TTM)
-1.303
Free cash flow yield (TTM)
-76.73%
Free cash flow per share (TTM)
-1.289
Growth
Revenue change (TTM)
59.81%
Earnings per share change (TTM)
476.38%
3-year revenue growth (CAGR)
-41.54%
10-year revenue growth (CAGR)
3.45%
3-year earnings per share growth (CAGR)
-27.47%
10-year earnings per share growth (CAGR)
-13.35%
What the Analysts think about Coherus Oncology
Analyst ratings (Buy, Hold, Sell) for Coherus Oncology stock.
Coherus Oncology Financial Performance
Revenues and expenses
Coherus Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coherus Oncology stock?
Coherus Oncology (CHRS) has a market cap of $252M as of March 19, 2026.
What is the P/E ratio for Coherus Oncology stock?
The price to earnings (P/E) ratio for Coherus Oncology (CHRS) stock is 1.17 as of March 19, 2026.
Does Coherus Oncology stock pay dividends?
No, Coherus Oncology (CHRS) stock does not pay dividends to its shareholders as of March 19, 2026.
When is the next Coherus Oncology dividend payment date?
Coherus Oncology (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus Oncology?
Coherus Oncology (CHRS) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.